Pierre Combe

4.2k total citations · 1 hit paper
42 papers, 1.5k citations indexed

About

Pierre Combe is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pierre Combe has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Reproductive Medicine and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pierre Combe's work include Ovarian cancer diagnosis and treatment (14 papers), Cancer Immunotherapy and Biomarkers (7 papers) and PARP inhibition in cancer therapy (6 papers). Pierre Combe is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Cancer Immunotherapy and Biomarkers (7 papers) and PARP inhibition in cancer therapy (6 papers). Pierre Combe collaborates with scholars based in France, Belgium and Japan. Pierre Combe's co-authors include Éric Tartour, Nadine Benhamouda, Anne Berger, Anne‐Laure Pointet, Elie Marcheteau, Julien Taı̈eb, Franck Zinzindohoué, Orianne Colussi, Mevyn Nizard and Magali Terme and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pierre Combe

37 papers receiving 1.5k citations

Hit Papers

VEGF-A modulates expression of inhibitory checkpoints on ... 2015 2026 2018 2022 2015 250 500 750

Peers

Pierre Combe
Pierre Combe
Citations per year, relative to Pierre Combe Pierre Combe (= 1×) peers Orianne Colussi

Countries citing papers authored by Pierre Combe

Since Specialization
Citations

This map shows the geographic impact of Pierre Combe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Combe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Combe more than expected).

Fields of papers citing papers by Pierre Combe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Combe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Combe. The network helps show where Pierre Combe may publish in the future.

Co-authorship network of co-authors of Pierre Combe

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Combe. A scholar is included among the top collaborators of Pierre Combe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Combe. Pierre Combe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oudard, Stéphane, Pierre Combe, Ali Hasbini, et al.. (2024). ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.. Journal of Clinical Oncology. 42(16_suppl). TPS5127–TPS5127. 1 indexed citations
2.
Cancel, Mathilde, et al.. (2024). FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer—A Multicenter Prospective Study. Journal of Clinical Oncology. 42(22). 2713–2722. 7 indexed citations
3.
Lazareth, Hélène, Nicolas Delanoy, Raphael M. Cohen, et al.. (2020). Nephrotoxicity Associated With Niraparib. American Journal of Kidney Diseases. 76(6). 898–900. 12 indexed citations
4.
Aide, Nicolas, Elodie Coquan, Gwénaël Ferron, et al.. (2020). Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging. 48(6). 1998–2008. 11 indexed citations
5.
Fournier, Marion, Cyrille Huchon, Charlotte Ngô, et al.. (2018). Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. Risk factor analysis. European Journal of Surgical Oncology. 44(6). 750–753. 19 indexed citations
6.
Ahmed, Sabrina Ben, Daniel Ghercă, Pierre Combe, et al.. (2017). Cryopreserved arterial allografts for in situ reconstruction of abdominal aortic native or secondary graft infection. Journal of Vascular Surgery. 67(2). 468–477. 39 indexed citations
7.
Granier, Clémence, Charles Dariane, Pierre Combe, et al.. (2016). Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Research. 77(5). 1075–1082. 163 indexed citations
8.
Pécuchet, Nicolas, Eleonora Zonta, Audrey Didelot, et al.. (2016). Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. PLoS Medicine. 13(12). e1002199–e1002199. 75 indexed citations
9.
Verret, Benjamin, Cécile Badoual, Pierre Combe, A. Carlotti, & Stéphane Oudard. (2016). Targeted Therapy’s Skin Toxicities after Immunotherapy: Skin Toxicity of Tyrosine Kinase Inhibitor Therapy Following Nilovumab Therapy for Metastatic Renal Cell Carcinoma. 1(1). 1 indexed citations
10.
Elaidi, Réza, Mustafa Özgüroğlu, Hélène Gauthier, et al.. (2016). Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study. Clinical Genitourinary Cancer. 15(3). e469–e476. 8 indexed citations
11.
Pujade-Lauraine, Éric & Pierre Combe. (2016). Recurrent ovarian cancer. Annals of Oncology. 27. i63–i65. 36 indexed citations
12.
Combe, Pierre, Éléonore De Guillebon, Constance Thibault, et al.. (2015). Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. OncoImmunology. 4(5). e1001236–e1001236. 19 indexed citations
13.
Pujade-Lauraine, Éric & Pierre Combe. (2015). Olaparib dans les cancers de l'ovaire avec mutation BRCA. Bulletin du Cancer. 102(6). S82–S84. 5 indexed citations
14.
Delanoy, Nicolas, Nicolas Pécuchet, Elizabeth Fabre, et al.. (2015). Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord–Stromal Tumors. International Journal of Gynecological Cancer. 25(9). 1593–1598. 16 indexed citations
15.
Combe, Pierre, L. Chauvenet, Marie‐Aude Lefrère‐Belda, et al.. (2015). Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. Investigational New Drugs. 33(6). 1267–1270. 23 indexed citations
16.
Badoual, Cécile, Pierre Combe, Alain Gey, et al.. (2013). Signification et intérêt clinique de l’expression de PD-1 et PDL-1 dans les tumeurs. médecine/sciences. 29(6-7). 570–572. 11 indexed citations
17.
Giraud, P., Philippe Meneï, Jacques Médioni, et al.. (2012). Carcinome rénal : état des lieux de la prise en charge des métastases cérébrales. Bulletin du Cancer. 99(6). 627–634. 2 indexed citations
18.
Vernejoux, J.‐M., et al.. (2001). Spontaneous pneumothorax : pragmatic management and long-term outcome. Respiratory Medicine. 95(11). 857–862. 13 indexed citations
19.
Mougenot, J. F., et al.. (1981). Maladie des chaînes lourdes alpha. Rémission complète d'un cas traité au stade de sarcome immunoblastique.. 38(6). 1 indexed citations
20.
Morand, Pierre, et al.. (1979). Myopathie lipidique avec cardiomyopathie sévère par déficit généralisé en carnitine. Evolution favorable sous un traitement par chlorhydrate de carnitine.. Archives Des Maladies Du Coeur Et Des Vaisseaux. 72(5). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026